ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Clinical trial NCT03686124 · RECRUITING

Trial details

NCT number: NCT03686124
Sponsor: Immatics US, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Refractory Cancer Recurrent Cancer Solid Tumor, Adult Cancer

Start date: 2019-05-14
Primary completion: 2028-12-01
Enrollment: 375

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.